About Morepen Laboratory:
This is a 30 years old pharmaceutical and healthcare product manufacturing company. Company is listed in both Bombay Stock Exchange and National Stock Exchange. Company is engaged in manufacturing and sales of APIs/Bulk drugs, home diagnostics, formulations and OTC products. The USFDA approved plant at Masulkhana is for manufacture of Loratadine, an anti-allergy drug, known as Claritin.
The companies OTC brand are being promoted by Dr. Morepen Ltd. and the famous OTC product line include Burnol, lemolate, Sat-Isabgol, Fever-X, Pain-X, and others have significant products in domestic market.
Morepen Laboratories Scores No. 1 position globally for its bulk drug Montelukast. Companies efficient operating results in over 25-fold increase in net profit for FY 2015-16.
For the financial year ended 31 March, 2016 the net profit increased from 58 lacks in FY 2014-15 to 15.78 crore in FY 2015-16. The total operating revenue in FY 2015-16 stood at Rs. 452.46 crore as against 370.26 crore in the previous fiscal. registering a growth of 22.20.
For the fourth quarter ended March 31, 2016 net profit rose to 2.77 crore on a total operating revenue of Rs. 123.59 crore as compared to loss of Rs. 3.77 crore on a total operating revenue of Rs. 85.36 crore in the corresponding quarter of the previous fiscal.
Morepen's EBIDTA increased by 36.30% in the fiscal 2015-16 at Rs. 65.38 crore and the cash surplus that is EBDTA Rose by 40% at Rs. 54.96 crore compared to Rs. 47.95 crore and Rs. 39.31 crore respectively, in the previous fiscal.
MOREPENLAB is in good buying zone. Company posted good yearly result this time and posted 15.78 crore profit on Y-O-Y basis as compared to last year profit that is only .58 cr. I am attaching the yearly results and current shareholding pattern. If you have 1-2 year horizon then keep accumulating this share and after 2 years you will be in huge profit.
